Teva’s generic Adderall XR capsules are indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
In August 2006, Teva’s subsidiary Barr Pharmaceuticals entered into a licensing agreement with Shire as part of a settlement of patent litigation between the parties. Under this agreement, Shire granted the company the exclusive right to sell a generic version of Adderall XR capsules for 180 days from the date of commercial launch.